Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6 ...

AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. At the moment, anyone with ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...